PHOSPHOLINE IODIDE
LOE Approachingechothiophate iodide for ophthalmic solution
NDAOPHTHALMICFOR SOLUTION
Approved
Jun 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Drug Shortage Active
PHOSPHOLINE IODIDE is currently in shortage. Reason: Available. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
PHOSPHOLINE IODIDE (echothiophate iodide for ophthalmic solution) is clinical pharmacology echothiophate iodide for ophthalmic solution is a long-acting cholinesterase inhibitor for topical use which enhances the effect of endogenously liberated acetylcholine in iris, ciliary muscle, and other parasympathetically innervated structures of the eye. Approved for elevated iop. First approved in 1960.
Drug data last refreshed 52m ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Phospholine Iodide (echothiophate iodide) is a long-acting cholinesterase inhibitor ophthalmic solution approved in 1960 for topical use in the eye. It treats elevated intraocular pressure by enhancing acetylcholine effects, causing miosis and increased aqueous humor outflow. The drug potentiates accommodation and lowers IOP through parasympathomimetic action on iris and ciliary muscle.
$0.942MPart D
LOE ApproachingUltra-niche, declining-use product with minimal market footprint suggests small, specialized team focused on legacy patient support rather than growth.
Mechanism of Action
CLINICAL PHARMACOLOGY Echothiophate iodide for ophthalmic solution is a long-acting cholinesterase inhibitor for topical use which enhances the effect of endogenously liberated acetylcholine in iris, ciliary muscle, and other parasympathetically innervated structures of the eye. It thereby causes…
Indications (1)
Career Relevance
Working on Phospholine Iodide offers limited career growth due to minimal market presence (368 Part D claims, $942K spend) and approaching LOE. Roles are primarily focused on maintaining existing patient access, managing shortages, and supporting legacy prescribers rather than driving innovation or revenue growth.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.